Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor

Abstract

The cholecystokinin 2 receptor (CCK2R) increases proliferation of normal and neoplastic gastrointestinal cells and activates various mitogenic signaling pathways when stimulated by gastrin. To study the incidence of permanent activation of this receptor in tumorigenicity, a constitutively active mutant was generated by replacing residue Glu151 in the conserved E/DRY motif by Ala. Expression of the E151A-CCK2R mutant in NIH-3T3 cells causes ligand-independent activation of phospholipase C and ornithine decarboxylase, two enzymes critical for mitogenesis. Strikingly, the constitutive activity of this mutant was associated with dramatic alteration of NIH-3T3 cell morphology, enhanced cell proliferation and invasion. Moreover, injection of cells expressing E151A-CCK2R in nude mice resulted in the development of large and rapidly growing tumors. By contrast, none of these effects was observed with cells expressing the wild-type CCK2R, indicating that the tumorigenic properties of the E151A-CCK2R mutant is the result of its constitutive activation. To date, this is the first report that provides evidence for the high tumorigenic effect of a constitutively active CCK2R mutant, thus raising a potential role of the CCK2R in human cancer.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM and McEwan RN . (1987). Cancer Res., 47, 3239–3245.

  • Alewijnse AE, Timmerman H, Jacobs EH, Smit MJ, Roovers E, Cotecchia S and Leurs R . (2000). Mol. Pharmacol., 57, 890–898.

  • Allen LF, Lefkowitz RJ, Caron MG and Cotecchia S . (1991). Proc. Natl. Acad. Sci. USA, 88, 11354–11358.

  • Auvinen M, Laine A, Paasinen-Sohns A, Kangas A, Kangas L, Saksela O, Andersson LC and Holtta E . (1997). Cancer Res., 57, 3016–3025.

  • Auvinen M, Paasinen A, Andersson LC and Holtta E . (1992). Nature, 360, 355–358.

  • Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka EG, Gutkind JS, Asch AS, Cesarman E, Gershengorn MC, Mesri EA and Gerhengorn MC . (1998). Nature, 391, 86–89.

  • Burger M, Burger JA, Hoch RC, Oades Z, Takamori H and Schraufstatter IU . (1999). J. Immunol., 163, 2017–2022.

  • Caplin M, Savage K, Khan K, Brett B, Rode J, Varro A and Dhillon A . (2000). Br. J. Surg., 87, 1035–1040.

  • Clerc P, Leung-Theung-Long S, Wang TC, Dockray GJ, Bouisson M, Delisle MB, Vaysse N, Pradayrol L, Fourmy D and Dufresne M . (2002). Gastroenterology, 122, 428–437.

  • Cohen GB, Yang T, Robinson PR and Oprian DD . (1993). Biochemistry, 32, 6111–6115.

  • Dhanasekaran N, Heasley LE and Johnson GL . (1995). Endocr. Rev., 16, 259–270.

  • Ding WQ, Kuntz SM and Miller LJ . (2002). Cancer Res., 62, 947–952.

  • Estep RD, Axthelm MK and Wong SW . (2003). J. Virol., 77, 1738–1746.

  • Fourmy D, Lopez P, Poirot S, Jimenez J, Dufresne M, Moroder L, Powers SP and Vaysse N . (1989). Eur. J. Biochem., 185, 397–403.

  • Gales C, Kowalski-Chauvel A, Dufour MN, Seva C, Moroder L, Pradayrol L, Vaysse N, Fourmy D and Silvente-Poirot S . (2000). J. Biol. Chem., 275, 17321–17327.

  • Gether U, Kobilka BK . (1998). J. Biol. Chem., 273, 17979–17982.

  • Gether U . (2000). Endocr Rev., 21, 90–113.

  • Gutkind JS, Novotny EA, Brann MR and Robbins KC . (1991). Proc. Natl. Acad. Sci. USA, 88, 4703–4707.

  • Hellmich MR, Rui XL, Hellmich HL, Fleming RY, Evers BM and Townsend Jr CM . (2000). J. Biol. Chem., 275, 32122–32128.

  • Holtta E, Auvinen M and Andersson LC . (1993). J. Cell. Biol., 122, 903–914.

  • Holtta E, Sistonen L and Alitalo K . (1988). J. Biol. Chem., 263, 4500–4507.

  • Hunyady L, Vauquelin G, Vanderheyden P . (2003). Trends Pharmacol. Sci., 24, 81–86.

  • Julius D, Livelli TJ, Jessell TM and Axel R . (1989). Science, 244, 1057–1062.

  • Kenakin T . (2002). Annu. Rev. Pharmacol. Toxicol., 42, 349–379.

  • Melchiori A, Carlone S, Allavena G, Aresu O, Parodi S, Aaronson SA and Albini A . (1990). Anticancer Res., 10, 37–44.

  • Morin D, Cotte N, Balestre MN, Mouillac B, Manning M, Breton C and Barberis C . (1998). FEBS Lett., 441, 470–475.

  • Moroder L, Wilschowitz L, Gemeiner M, Gohring W, Knof S, Scharf R, Thamm P, Gardner JD, Solomon TE and Wunsch E . (1981). Hoppe Seylers Z. Physiol. Chem., 362, 929–942.

  • Munson PJ and Rodbard D . (1980). Anal. Biochem., 107, 220–239.

  • Pagliocca A, Wroblewski LE, Ashcroft FJ, Noble PJ, Dockray GJ and Varro A . (2002). Am. J. Physiol. Gastrointest. Liver Physiol., 283, G292–G299.

  • Parma J, Van Sande J, Swillens S, Tonacchera M, Dumont J and Vassart G . (1995). Mol. Endocrinol., 9, 725–733.

  • Parnot C, Miserey-Lenkei S, Bardin S, Corvol P and Clauser E . (2002). Trends Endocrinol. Metab., 8, 336–343.

  • Pohl M, Silvente-Poirot S, Pisegna JR, Tarasova NI and Wank SA . (1997). J. Biol. Chem., 272, 18179–18184.

  • Pyronnet S, Gingras AC, Bouisson M, Kowalski-Chauvel A, Seva C, Vaysse N, Sonenberg N and Pradayrol L . (1998). Oncogene, 16, 2219–2227.

  • Radhika V and Dhanasekaran N . (2001). Oncogene, 20, 1607–1614.

  • Rasmussen SG, Jensen AD, Liapakis G, Ghanouni P, Javitch JA and Gether U . (1999). Mol. Pharmacol., 56, 175–184.

  • Reubi JC, Schaer JC and Waser B . (1997). Cancer Res., 57, 1377–1386.

  • Rozengurt E and Walsh JH . (2001). Annu. Rev. Physiol., 63, 49–76.

  • Samama P, Bond RA, Rockman HA, Milano CA and Lefkowitz RJ . (1997). Proc. Natl. Acad. Sci. USA, 94, 137–141.

  • Scemama JL, De Vries L, Pradayrol L, Seva C, Tronchere H and Vaysse N . (1989). Am. J. Physiol. Gastrointest. Liver Physiol., 256, G846–G850.

  • Scheer A, Fanelli F, Costa T, De Benedetti PG and Cotecchia S . (1996). EMBO J., 15, 3566–3578.

  • Schmitz F, Otte JM, Stechele HU, Reimann B, Banasiewicz T, Folsch UR, Schmidt WE and Herzig KH . (2001). Eur. J. Clin. Invest., 31, 812–820.

  • Silvente-Poirot S, Escrieut C, Gales C, Fehrentz JA, Escherich A, Wank SA, Martinez J, Moroder L, Maigret B, Bouisson M, Vaysse N and Fourmy D . (1999). J. Biol. Chem., 274, 23191–23197.

  • Sistonen L, Holtta E, Lehvaslaiho H, Lehtola L and Alitalo K . (1989). J. Cell. Biol., 109, 1911–1919.

  • Smith AM and Watson SA . (2000). Gut, 47, 820–824.

  • Stepan VM, Dickinson CJ, del Valle J, Matsushima M and Todisco A . (1999). Am. J. Physiol. Gastrointest. Liver Physiol., 276, G1363–G1372.

  • Todisco A, Takeuchi Y, Seva C, Dickinson CJ and Yamada T . (1995). J. Biol. Chem., 270, 28337–28341.

  • Wank SA . (1998). Am. J. Physiol. Gastrointest. Liver Physiol., 274, G607–G613.

  • Whitehead IP, Zohn IE and Der CJ . (2001). Oncogene, 20, 1547–1555.

  • Yang TY, Chen SC, Leach MW, Manfra D, Homey B, Wiekowski M, Sullivan L, Jenh CH, Narula SK, Chensue SW and Lira SA . (2000). J. Exp. Med., 191, 445–454.

  • Zhuge Y and Xu J . (2001). J. Biol. Chem., 276, 16248–16256.

Download references

Acknowledgements

We thank Hubert Lulka for excellent technical support, Dr Philippe Rochaix for histological analyses of tumors and Dr Hervé Paris for carefully reading the manuscript. This work was supported in part by a grant from the Association pour la Recherche sur le Cancer (ARC 5481).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sandrine Silvente-Poirot.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galés, C., Sanchez, D., Poirot, M. et al. High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor. Oncogene 22, 6081–6089 (2003). https://doi.org/10.1038/sj.onc.1206823

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206823

Keywords

Search

Quick links